SOCS-2 expression in patients with chronic myeloid leukemia in blast crisis or Ph-positive acute lymphocytic leukemia under STI571 therapy
| Patient no. . | Diagnosis . | Days on STI571 . | % of blasts . | SOCS-2/GAPDH ratio . | |
|---|---|---|---|---|---|
| PB . | BM . | ||||
| 1 | CML-BC | 0 | 42 | 40 | 3.2 |
| (myeloid) | 8 | 12 | nd | 0.2 | |
| 2 | CML-BC | 0 | 23 | 60 | 7.2 |
| (myeloid) | 7 | 4 | nd | 2.7 | |
| 14 | 0 | nd | 1.4 | ||
| 3 | CML-BC | 0 | 25 | 50 | 3.7 |
| (myeloid) | 4 | 42 | nd | 3.0 | |
| 11 | 11 | nd | 5.9 | ||
| 20 | 15 | 35 | 0.9 | ||
| 49 | 4 | nd | 0.8 | ||
| 84 | 4 | 15 | 0.7 | ||
| 4 | CML-BC | 0 | 9 | 70 | 20.5 |
| (myeloid) | 21 | 4 | nd | 5.0 | |
| 28 | 0 | nd | 6.4 | ||
| 113 | 0 | 6 | 5.8 | ||
| 5 | CML-BC | 0 | 44 | 25 | 6.1 |
| (myeloid) | 36 | nd | 2 | 4.4 | |
| 43 | 0 | nd | 4.1 | ||
| 50 | 0 | nd | 5.2 | ||
| 85 | 0 | 1 | 0.3 | ||
| 6 | CML-BC | 0 | 34 | 100 | 16.4 |
| (myeloid) | 35 | 5 | 10 | 5.3 | |
| 56 | nd | 0 | 2.2 | ||
| 7 | CML-BC | 0 | 6 | 30 | 4.4 |
| (myeloid) | 26 | nd | 10 | 5.6 | |
| 8 | CML-BC | 0 | 66 | 50 | 6.0 |
| (myeloid) | 5 | 79 | nd | 5.9 | |
| 9 | CML-BC | 0 | 48 | 80 | 7.8 |
| (myeloid) | 26 | 62 | 70 | 29.6 | |
| 82 | nd | 80 | 23.3 | ||
| 10 | CML-BC | 0 | 16 | 32 | 5.0 |
| (myeloid) | 25 | nd | 32 | 4.5 | |
| 11 | CML-BC | 0 | 15 | 90 | 30.1 |
| (lymphoid) | 113 | 0 | 20 | 8.2 | |
| 12 | Ph+ ALL | 0 | 19 | 95 | 15.5 |
| 28 | nd | 20 | 2.9 | ||
| 63 | 0 | 36 | 3.1 | ||
| 13 | Ph+ ALL | 0 | 8 | 90 | 2.4 |
| 7 | nd | nd | 1.0 | ||
| 35 | nd | 18 | 1.8 | ||
| 58 | nd | 80 | 15.1 | ||
| 14 | Ph+ ALL | 0 | 78 | 80 | 0.3 |
| 71 | nd | 2 | 0.1 | ||
| Patient no. . | Diagnosis . | Days on STI571 . | % of blasts . | SOCS-2/GAPDH ratio . | |
|---|---|---|---|---|---|
| PB . | BM . | ||||
| 1 | CML-BC | 0 | 42 | 40 | 3.2 |
| (myeloid) | 8 | 12 | nd | 0.2 | |
| 2 | CML-BC | 0 | 23 | 60 | 7.2 |
| (myeloid) | 7 | 4 | nd | 2.7 | |
| 14 | 0 | nd | 1.4 | ||
| 3 | CML-BC | 0 | 25 | 50 | 3.7 |
| (myeloid) | 4 | 42 | nd | 3.0 | |
| 11 | 11 | nd | 5.9 | ||
| 20 | 15 | 35 | 0.9 | ||
| 49 | 4 | nd | 0.8 | ||
| 84 | 4 | 15 | 0.7 | ||
| 4 | CML-BC | 0 | 9 | 70 | 20.5 |
| (myeloid) | 21 | 4 | nd | 5.0 | |
| 28 | 0 | nd | 6.4 | ||
| 113 | 0 | 6 | 5.8 | ||
| 5 | CML-BC | 0 | 44 | 25 | 6.1 |
| (myeloid) | 36 | nd | 2 | 4.4 | |
| 43 | 0 | nd | 4.1 | ||
| 50 | 0 | nd | 5.2 | ||
| 85 | 0 | 1 | 0.3 | ||
| 6 | CML-BC | 0 | 34 | 100 | 16.4 |
| (myeloid) | 35 | 5 | 10 | 5.3 | |
| 56 | nd | 0 | 2.2 | ||
| 7 | CML-BC | 0 | 6 | 30 | 4.4 |
| (myeloid) | 26 | nd | 10 | 5.6 | |
| 8 | CML-BC | 0 | 66 | 50 | 6.0 |
| (myeloid) | 5 | 79 | nd | 5.9 | |
| 9 | CML-BC | 0 | 48 | 80 | 7.8 |
| (myeloid) | 26 | 62 | 70 | 29.6 | |
| 82 | nd | 80 | 23.3 | ||
| 10 | CML-BC | 0 | 16 | 32 | 5.0 |
| (myeloid) | 25 | nd | 32 | 4.5 | |
| 11 | CML-BC | 0 | 15 | 90 | 30.1 |
| (lymphoid) | 113 | 0 | 20 | 8.2 | |
| 12 | Ph+ ALL | 0 | 19 | 95 | 15.5 |
| 28 | nd | 20 | 2.9 | ||
| 63 | 0 | 36 | 3.1 | ||
| 13 | Ph+ ALL | 0 | 8 | 90 | 2.4 |
| 7 | nd | nd | 1.0 | ||
| 35 | nd | 18 | 1.8 | ||
| 58 | nd | 80 | 15.1 | ||
| 14 | Ph+ ALL | 0 | 78 | 80 | 0.3 |
| 71 | nd | 2 | 0.1 | ||
Levels of SOCS-2, expressed as a ratio ofSOCS-2/GAPDH, are correlated with the duration of treatment and the response to STI571 therapy as assessed by the percentage of blasts in the peripheral blood or bone marrow.
GAPDH indicates glyceraldehyde phosphate dehydrogenase; CML-BC, chronic myeloid leukemia in blast crisis; PB, peripheral blood; BM, bone marrow; nd, not determined; and Ph+ ALL, PH-positive acute lymphocytic leukemia.